Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT06226272
Recruiting Observational

Clinical Outcome Measure at Stryker Spine

NCT06226272 · tracked via the Priya Life Science USA tracker
Sponsor
VB Spine, LLC
Phase
Observational
Started
2025-01-28
Last updated
2026-06-26

Condition(s) studied

Degenerative Disc DiseaseDegenerative Scoliosis

Investigational drug(s) / intervention(s)

Spinal FusionSpinal FusionSpinal Deformities Correction

Spinal Fusion: Cervical Spinal Fusion

Spinal Fusion: Thoracic / Lumbar Spinal Fusion

Spinal Deformities Correction: Spinal Deformities Correction

Study summary

This is a multicenter, prospective, retrospective, Post Market Clinical Follow-up (PMCF) study in subjects who have undergone or will undergo surgery utilizing one or more Stryker devices according to Stryker cleared Instructions for Use (IFU).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: • To be eligible to participate in the study, the potential subject must meet all inclusion criteria specific to the Stryker system being evaluated, please contact one of the participating investigators or see the device-specific cleared IFU, for further details. Exclusion Criteria: • The exclusion criteria are based on the contraindications as presented in the Stryker device cleared IFUs, please contact one of the participating investigators or see the device-specific cleared IFU, for further details.

Primary outcome measure(s)

  • S-S-102-A — Baseline through 24-months post-op.
    Mean change in the subject's Neck Disability Index (NDI) score.
  • S-S-102-B — Baseline through 24-months post-op.
    Mean change in the subject's Oswestry Disability Index (ODI) score.
  • S-S-102-C — Baseline through 24-months post-op.
    Mean change in the subject's Scoliosis Research Society-22 revised (SRS-22r).

Trial sites (7)

FacilityCityRegionStatus
Mayo Clinic Florida Jacksonville Florida Recruiting
MaineHealth Neurosurgery and Spine Scarborough Maine Recruiting
Michigan Orthopaedic Surgeons Southfield Michigan Recruiting
Cleveland Clinc Cleveland Ohio Recruiting
Vanderbilt University Medical Center Nashville Tennessee Recruiting
Texas Spine & Scoliosis Austin Texas Recruiting
The University of Texas Health Science Center at Houston Houston Texas Recruiting

Other trials for the same condition

Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion Enrolling by invitation
Assessing Safety of Cervical Spine Fusion With NMP® Starting soon
Long-Term Assessment of the Safety and Performance of the NuVasive Simplify Disc at Two Levels Enrolling by invitation
Long-term Assessment of the Safety and Performance of the NuVasive Simplify Disc Active, not recruiting
Study of Posterior Cervical Stabilization System (PCSS) as Part of Circumferential Fusion to Treat Multilevel DDD Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06226272 on ClinicalTrials.gov ↗ ← All trials in the USA